Document is current
Any future updates will be listed below
-
Authors
Sen, Chandani
Rickabaugh, Tammy M.
Jeyachandran, Arjit Vijey
Yuen, Constance
Ghannam, Maisam
Durra, Abdo
Aziz, Adam
Castillo, Kristen
Garcia, Gustavo Jr.
Purkayastha, Arunima
Han, Brandon
Boulton, Felix W.
Chekler, Eugene
Garces, Robert
Wolff, Karen C.
Riva, Laura
Kirkpatrick, Melanie G.
Gebara-Lamb, Amal
McNamara, Case W.
Betz, Ulrich A. K.
Arumugaswami, Vaithilingaraja
Damoiseaux, Robert
Gomperts, Brigitte N. https://orcid.org/0000-0002-1809-723X
-
Funding
Funding for this research was provided by:
Merck KGaA, Darmstadt, Germany
Bill & Melinda Gates Foundation
California Institute of Regenerative Medicine (DISC2 19-11764)
The Department of Defense (PR202868)
UCLA Oversight COVID-19 Research Committee
NIH/NCI (R01CA208303)
Mercatus Center Fast Grants for COVID-19 research
UCOP Emergency Funding COVID19 TRDRP Seed grant (R00RG2383)
UCLA Eli & Edythe Broad Center of Stem Cell Research
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 1 January 2025
First Online: 16 January 2025
Declarations
:
: All research was conducted in accordance with the declaration of Helsinki. All patient samples used in this study were de-identified and were collected with an Institutional Review Board (IRB) exemption. The need for consent was waived by the IRB. Patient large airways and bronchial tissues were acquired from three different tissue sources: 1. de-identified normal human donors after lung transplantations at the Ronald Reagan UCLA Medical Center. Tissues were procured under an Institutional Review Board-approved protocol at the David Geffen School of Medicine at UCLA (IRB#21-000390-CR-00003). 2. Normal human bronchial epithelial cells (NHBE) from non-smokers were obtained from Lonza and all samples were de-identified. 3. Deidentified donor lung and trachea samples from the International Institute for the Advancement of Medicine (IIAM) were obtained with institutional approval. All animal studies were carried out according to the standard operating procedure in place at the test facility at Vibiosphen. All procedures were performed in accordance with the Directive 2010/63/UE recommendations and with French Veterinary Authorities agreement. All animals were managed similarly, with due regard for their well-being, according to prevailing practices and the current SOPs in force at Vibiosphen. The in vivo design and procedures were approved by Ethical Committee.
: Not applicable.
: Ulrich AK Betz, Eugene Chekler, and Robert Garces are or were employees of Merck KGaA, Darmstadt, Germany, or its affiliated companies and there is a patent application associated with this work. Brigitte Gomperts is a co-founder and consultant for InSpira LLC. Other authors declare no competing financial interests.
